期刊文献+

前列地尔治疗慢性肾功能衰竭的临床观察 被引量:7

前列地尔治疗慢性肾功能衰竭的临床观察
下载PDF
导出
摘要 目的:观察前列地尔注射液治疗慢性肾功能衰竭的临床疗效。方法:选择40例均未透析慢性肾衰竭住院患者在常规用药基础上给予前列地尔注射液10ug,每天1次,疗程10~14天,观察治疗前后血尿素氮(BUN)、血肌酐(SCr)、肌酐清除率(Ccr)和24小时尿蛋白定量变化。结果:治疗后血尿素氮(BUN)、血肌酐(SCr)较治疗前明显下降(p【0.01),肌酐清除率(Ccr)较治疗前明显上升(P【0.01),24小时尿蛋白定量较治疗前明显减少(P【0.01)。结论:前列地尔注射液有利于减缓慢性肾衰的进展。 Objective:To observe the clinical efficacy of injection of alprostadil in the treatment of chronic renal failure . Methods: 40 cases of non-dialysis chronic renal failure patients with conventional drugs given 10ug alprostadil once a day, 10-14 days as a course, contrast the concentration of the blood urea nitrogen (BUN), creatinine (SCr), creatinine clearance rate(Ccr), 24-hour urinary protein before and after the treatment. Results:The blood urea nitrogen (BUN), serum creatinine (SCr) decreased significantly than prior treatment (p<0.01), creatinine clearance rate (Ccr) increased significantly than prior treatment (P<0.01), 24 hours urinary protein reduced significantly than the pre-treatment (P<0.01). Conclusion:alprostadil may prevent the progression of chronic renal failure .
作者 闵群燕
出处 《内蒙古中医药》 2009年第3X期62-63,共2页 Inner Mongolia Journal of Traditional Chinese Medicine
关键词 前列地尔 肾功能衰竭 Alprostadil renal failure chronic
  • 相关文献

参考文献3

二级参考文献15

  • 1Cawello W,Leonhardt A,Schweer H,etal.Dose proportional pharmacokinetics of alpro-stadil (prostaglandin E1)in healthyvolunteers following intravenous infusion 〔J〕.Br J Clin Pharmacol,1995,40:273~276.
  • 2Anggard E.The biological activities of three metabolites of prostaglandin E1 〔J〕.ActaPhysiol Scand,1996,66:509~510.
  • 3Yasuda H,Maeda K,Sonobe M,et al.Metabolic effect of PGE1 analogue O1206.αCD onnerve Na+-K+-ATPase activity of rats with streptozotocin-induced diabetes is mediatedvia cAMP: possible role of cAMP in diabetic neuropathy 〔J〕.Prostaglandins,1994,47:367~378.
  • 4Okada S,Ichiki K,Tanokuchi S,et al.Effect of prostaglandin E1 on therenin-aldosterone system in patients with diabetic nephropathy 〔J〕.J Int MedRes,1993,21:126~132.
  • 5Young MJ, Veves A,Smith JV, et al.Restoring lower limb blood flow improvesconduction velocity in diabetic patients 〔J〕.Diabetologia,1995,38:1051~1054.
  • 6Partanen J,Niskanen L,Lehtinen J,et al.Natural history of peripheral neuropathy inpatients with non-insulin-dependent diabetes mellitus 〔J〕. N Engl J Med,1995,333:89~94.
  • 7Yasuda H,Sonobe M,Hatanaka I,et al.A new prostaglandin E1 analogue (TFC-612)prevents a decrease in motor conduction velocity in streptozocin-diabetic rats 〔J〕.BiochemBiophys Res Commun,1998,150:225~230.
  • 8Shindo H,Tawata M,Inoue M,et al.The effect of prostaglandin E1.αCD on vibratorythreshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy 〔J〕.DiabetesRes Clin Pract,1994,24:173~180.
  • 9Okada S,Sato K,Higuchi T,et al.Influence of prostaglandin E1 on slight proteinuriain non-azotaemic diabetes 〔J〕.J Int Med Res,1992,20:94~97.
  • 10Creutzig A,Bullinger M,Cachovan M,et al.Improvement in the quality of life afteri.v.PGE1 therapy for intermittent claudication 〔J〕.Vasa,1997,26:122~127.

共引文献118

同被引文献48

引证文献7

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部